{
    "xml": "<topic id=\"PHP98029\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/hapoctasin\" basename=\"hapoctasin\" title=\"Hapoctasin\">\n<title>Hapoctasin<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP98279\" outputclass=\"indicationsAndDose\" rev=\"1.36\" parent=\"/clinical-medicinal-product-information/hapoctasin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate to severe chronic cancer pain</p>\n<p outputclass=\"therapeuticIndication\">Severe pain unresponsive to non-opioid analgesics</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By transdermal application using patches</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 35&#8239;micrograms/hour up to every 72&#8239;hours, in patients who <b>have not</b> previously received a strong opioid analgesic, for patients who <b>have</b> received strong opioid analgesic, the initial dose should be based on previous 24-hour opioid requirement, consult product literature, dose adjustment&#8212;when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)&#8212;if necessary, dose should be adjusted at intervals of no longer than 72 hours using a patch of the next strength or using 2 patches of the same strength (applied at <i>same time</i> to avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200&#8211;400 micrograms buprenorphine sublingually.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"pharmacokinetics\">\n<title>Pharmacokinetics</title>\n<p>It may take approximately 25 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP98286\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/clinical-medicinal-product-information/hapoctasin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>In view of the long duration of action, patients who have severe side-effects should be monitored for up to 25 hours after removing patch.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP98288\" outputclass=\"directionsForAdministration\" rev=\"1.8\" parent=\"/clinical-medicinal-product-information/hapoctasin\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after no longer than 72 hours and siting replacement patch on a different area (avoid same area for at least 7 days).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP98291\" outputclass=\"patientAndCarerAdvice\" rev=\"1.11\" parent=\"/clinical-medicinal-product-information/hapoctasin\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients or carers should be given advice on how to administer buprenorphine transdermal patches.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP98029",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/hapoctasin",
    "basename": "hapoctasin",
    "title": "Hapoctasin",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Moderate to severe chronic cancer pain",
                        "html": "Moderate to severe chronic cancer pain"
                    },
                    {
                        "textContent": "Severe pain unresponsive to non-opioid analgesics",
                        "html": "Severe pain unresponsive to non-opioid analgesics"
                    }
                ],
                "specificity": {
                    "routes": [
                        "transdermal application using patches"
                    ],
                    "textContent": "By transdermal application using patches",
                    "html": "By transdermal application using patches"
                },
                "adult": [
                    {
                        "textContent": "Initially 35 micrograms/hour up to every 72 hours, in patients who have not previously received a strong opioid analgesic, for patients who have received strong opioid analgesic, the initial dose should be based on previous 24-hour opioid requirement, consult product literature, dose adjustment&#8212;when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)&#8212;if necessary, dose should be adjusted at intervals of no longer than 72 hours using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200&#8211;400 micrograms buprenorphine sublingually.",
                        "html": "<p>Initially 35&#8239;micrograms/hour up to every 72&#8239;hours, in patients who <b>have not</b> previously received a strong opioid analgesic, for patients who <b>have</b> received strong opioid analgesic, the initial dose should be based on previous 24-hour opioid requirement, consult product literature, dose adjustment&#8212;when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)&#8212;if necessary, dose should be adjusted at intervals of no longer than 72 hours using a patch of the next strength or using 2 patches of the same strength (applied at <i>same time</i> to avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200&#8211;400 micrograms buprenorphine sublingually.</p>"
                    }
                ]
            }
        ],
        "pharmacokinetics": [
            {
                "type": "pharmacokinetics",
                "title": "Pharmacokinetics",
                "textContent": "It may take approximately 25 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.",
                "html": "<p>It may take approximately 25 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.</p>"
            }
        ]
    },
    "sideEffects": {
        "advice": [
            {
                "type": "advice",
                "textContent": "In view of the long duration of action, patients who have severe side-effects should be monitored for up to 25 hours after removing patch.",
                "html": "<p>In view of the long duration of action, patients who have severe side-effects should be monitored for up to 25 hours after removing patch.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after no longer than 72 hours and siting replacement patch on a different area (avoid same area for at least 7 days).",
                "html": "<p>Apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after no longer than 72 hours and siting replacement patch on a different area (avoid same area for at least 7 days).</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients or carers should be given advice on how to administer buprenorphine transdermal patches.",
                "html": "<p>Patients or carers should be given advice on how to administer buprenorphine transdermal patches.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}